Literature DB >> 28828943

From a global crisis to the 'end of AIDS': New epidemics of signification.

Nora Kenworthy1, Matthew Thomann2, Richard Parker3,4.   

Abstract

In the past decade, discourses about AIDS have taken a remarkable, and largely unquestioned, turn. Whereas mobilisations for treatment scale-up during the 2000s were premised on perceptions of an 'epidemic out of control', we have repeatedly been informed in more recent years that an end to AIDS is immanent. This new discourse and its resulting policies are motivated by post-recession financial pressures, a changing field of global institutions, and shifting health and development priorities. These shifts also reflect a biomedical triumphalism in HIV prevention and treatment, whereby shorter term, privatised, technological, and 'cost-effective' interventions are promoted over long-term support for antiretroviral treatment. To explore these changes, we utilise Treichler's [(1987). How to have theory in an epidemic: Cultural chronicles of AIDS. Durham, NC: Duke University Press] view of AIDS as an 'epidemic of signification' to develop a review of 'End of AIDS' discourses in recent years. We use this review to investigate the political and philanthropic interests served by efforts to rebrand and re-signify the epidemic. We also hold up these discourses against the realities of treatment access in resource-poor countries, where 'Ending AIDS' has not heralded the end of an epidemic per se, but rather the end of external support for treatment programmes, highlighting new difficulties for sustaining treatment in this new era of the epidemic.

Entities:  

Keywords:  End of AIDS; HIV and AIDS; HIV prevention and treatment; biomedical interventions; global health funding

Mesh:

Year:  2017        PMID: 28828943     DOI: 10.1080/17441692.2017.1365373

Source DB:  PubMed          Journal:  Glob Public Health        ISSN: 1744-1692


  9 in total

1.  When Diabetes Confronts HIV: Biological Sub-citizenship at a Public Hospital in Nairobi, Kenya.

Authors:  Edna Bosire; Emily Mendenhall; Gregory Barnabas Omondi; David Ndetei
Journal:  Med Anthropol Q       Date:  2018-09-12

2.  Chronicity, crisis, and the 'end of AIDS'.

Authors:  Thurka Sangaramoorthy
Journal:  Glob Public Health       Date:  2018-01-11

3.  From advocacy to austerity: The new role of the U.S. public sector in HIV drug development and access.

Authors:  Ryan Whitacre
Journal:  Glob Public Health       Date:  2019-12-19

4.  Political and Governance Challenges to Achieving Global HIV Goals with Injecting Drug Users: The Case of Pakistan.

Authors:  Hina Khalid; Ashley M Fox
Journal:  Int J Health Policy Manag       Date:  2019-05-01

5.  Pepfar 3.0's HIV testing policy in Côte d'Ivoire (2014 to 2018): fragmentation, acceleration and disconnection.

Authors:  Anne Bekelynck; Joseph Larmarange
Journal:  J Int AIDS Soc       Date:  2019-12       Impact factor: 5.396

6.  Understanding socio-sexual networks: critical consideration for HIVST intervention planning among men who have sex with men in Kenya.

Authors:  Lisa Lazarus; Ravi Prakash; Bernadette K Kombo; Matthew Thomann; Kennedy Olango; Martin K Ongaro; Samuel Kuria; Memory Melon; Helgar Musyoki; Souradet Shaw; Parinita Bhattacharjee; Robert Lorway
Journal:  BMC Public Health       Date:  2022-03-21       Impact factor: 4.135

7.  Care during ART scale-up: surviving the HIV epidemic in Ethiopia.

Authors:  Makoto Nishi
Journal:  Biosocieties       Date:  2022-10-03

8.  Anachronic: Viral Socialities and Project Time among HIV Support Groups in Barbados.

Authors:  David A B Murray
Journal:  Med Anthropol Q       Date:  2022-03-09

9.  HIV testing amid COVID-19: community efforts to reach men who have sex with men in three Kenyan counties.

Authors:  Manas Migot Odinga; Samuel Kuria; Oliver Muindi; Peter Mwakazi; Margret Njraini; Memory Melon; Bernadette Kombo; Shem Kaosa; Japtheth Kioko; Janet Musimbi; Helgar Musyoki; Parinita Bhattacharjee; Robert Lorway
Journal:  Gates Open Res       Date:  2020-10-29
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.